Monitor whether the sale actually executes; a single officer sale of this size is routine and not indicative of broader insider sentiment. Watch for any subsequent Form 4 filings to confirm completion.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $27.00entry
- T+1 · 11d ago −5.37%α −5.68% · $25.55
- T+5 · 5d ago +1.96%α −1.33% · $27.53
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Masaru Matsuda, an officer of Arcutis Biotherapeutics, filed a Form 144 notice of intent to sell 40,000 shares of common stock, with an approximate market value of $1.37 million based on the filing date. The shares were acquired via stock option exercise on January 12, 2024, and the sale is planned for execution on or around November 4, 2026. This represents a relatively small portion of the company's $3.9B market cap and follows recent insider sales totaling $127K in the prior 30 days.
Key Facts
- Officer Masaru Matsuda filed Form 144 to sell 40,000 shares of common stock.
- Estimated sale value: approximately $1,372,670.48 based on filing date price.
- Shares acquired via stock option exercise on January 12, 2024.
- Proposed sale date: November 4, 2026.
- Recent insider activity: 1 sell totaling $127K in the 30 days prior to snapshot.
- Market cap: $3.9B; sale represents ~0.035% of shares outstanding.
Financial Impact
Proposed sale of 40,000 shares worth approximately $1.37 million, or about 0.035% of market cap.
Risk Factors
- Form 144 is an intent to sell; the sale may not occur.
- Insider selling could signal lack of confidence if followed by additional filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-070283 |
| Document: 0001628280-26-070283-index.html | 0001628280-26-070283 |
| Document: 0001628280-26-070283.txt | 0001628280-26-070283 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Viewing Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers